| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 2, 2024 10:00 A.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2022 | $25.00 → $15.00 | Overweight | Cantor Fitzgerald |
| 11/24/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.001 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $85 million. All of the shares of common stock and pre-funded
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET. To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life
IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 120 participants approximately four months earlier than originally planned. "We are very pleased to achieve this critical milestone ahead of schedule in our BESTOW trial," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "Th
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno
Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter operating and financial results and reviewed recent business highlights. "Eledon made significant progress this year in advancing the clinical developmen
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details: Thursday, May 11, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 888-886-7786International: 416-764-8658Conference ID: 11107025Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one year. About Eledon Phar
HC Wainwright & Co. analyst Vernon Bernardino reiterates Eledon Pharma (NASDAQ:ELDN) with a Buy and maintains $16 price target.
Gainers Akso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.43% to $1.27. The company's market cap stands at $1.1 million. CareCloud (NASDAQ:CCLD) stock increased by 10.07% to $2.84. The company's market cap stands at $45.7 million. The company's, Q1 earnings came out 3 days ago. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 9.63% to $3.31. The company's market cap stands at $125.5 million. OneMedNet (NASDAQ:ONMD) shares increased by 7.52% to $0.5. The market value of their outstanding shares is at $11.9 million. Reshape Lif
424B5 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
424B5 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
HC Wainwright & Co. reiterated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $35.00 previously
SVB Leerink reiterated coverage of Eledon Pharmaceuticals with a rating of Outperform and set a new price target of $33.00 from $34.00 previously
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)